A Phase Ib/II clinical evaluation of the safety and efficacy of combining panobinostat with 5-azacytidine in patients with high-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) that are unsuitable for standard induction chemotherapy.

Trial Profile

A Phase Ib/II clinical evaluation of the safety and efficacy of combining panobinostat with 5-azacytidine in patients with high-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) that are unsuitable for standard induction chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Azacitidine (Primary) ; Panobinostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2011 Evaluation of panobinostat 30mg + azacitidine of 75mg/m2 daily for 5 days is ongoing in the dose-expansion phase of this study.
    • 10 Dec 2011 Results of a planned interim analysis have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top